BridgeBio Pharma stock rises on Attruby sales and pipeline progress

au.investing.com

BridgeBio Pharma's stock is gaining momentum due to strong sales of its drug Attruby and a promising pipeline. Attruby generated $146 million in Q4 2025, with analysts projecting $875 million for fiscal year 2026. An intellectual property settlement extends Attruby's protection until mid-2031, boosting peak sales estimates. The company anticipates three regulatory approvals within a year, expanding its rare disease portfolio and moving towards projected profitability by 2028.


With a significance score of 0.9, this news ranks in the top 79% of today's 33195 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: